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Etiology 
Smallpox results from infection by variola virus (genus Orthopoxvirus, family 
Poxviridae). At least two strains of virus exist: the more virulent strain causes variola 
major and the less virulent strain causes variola minor. 
The Orthopoxvirus genus also includes the vaccinia, monkeypox, cowpox, 
camelpox and ectromelia viruses; these agents resemble each other in electron 
micrographs and in many culture systems. They are also serologically cross–reactive. 
Monkeypox, which usually found in Africa, closely resembles smallpox; in 
monkeypox infections, the mortality rate is lower and the cervical and inguinal lymph 
nodes are highly enlarged. 
Geographic Distribution 
The last naturally acquired case of smallpox occurred in 1977 and the last two 
laboratory–acquired infections in 1978. In 1980, the World Health Organization 
(WHO) declared that endemic smallpox had been eradicated. Currently, the only 
known stocks of virus are stored at the Centers for Disease Control and Prevention 
(CDC) in Atlanta and the Institute for Viral Preparations in Moscow. Other countries 
may have clandestine stores of virus. 
Transmission 
The smallpox virus must be continuously transmitted from human to human to 
survive; humans do not become long–term carriers and animal reservoirs do not exist. 
Virus is spread by direct contact or inhalation of aerosols; infectious virus is present 
in oronasal secretions and in scabs from the skin. (The virus in scabs may be tightly 
bound and spread by this method may be less efficient.) Close contact is usually 
required for efficient virus transmission; therefore, smallpox mainly spreads to 
household members and others in close contact. Variola viruses can also be 
transmitted by individuals who maintain the virus in the throat without clinical signs. 
The potential for long–distance aerosol spread is controversial but has been 
demonstrated under certain conditions such as in hospitals. Transmission on fomites 
such as contaminated clothing or bedclothes is possible for short periods of time; 
however, variola does not remain viable for more than 2 days outside a human host. It 
is sensitive to heat and humidity; most natural epidemics occurred in the winter and 
spring.  
Disinfection 
Variola virus is susceptible to various disinfectants including 1% sodium 
hypochlorite, 0.1N sodium hydroxide, 1% peracetic acid, formaldehyde, ethylene 
oxide and others. The virus can also be destroyed by autoclaving or boiling for 10 
minutes. 
Infections in Humans 
Incubation Period 
The incubation period is 7 to 19 days; 12 to 14 days is average. 
Clinical Signs 
Smallpox has an acute onset; the initial clinical signs may include fever, malaise, 
rigors, vomiting, headache, backache and occasionally delirium. Some people 
develop an erythematous rash during this prodromal phase. The characteristic skin 
lesions usually appear 2 to 3 days later; the first signs are macules, which develop into 
papules and eventually pustular vesicles. These lesions are most common on the face 
and extremities and develop in synchronous “crops.” Approximately 8 to 14 days 
after the first symptoms appeared, the pustules develop scabs and heal, leaving 
depressed, depigmented scars. Severe scarring may occur. 
Two forms of smallpox may be seen. Variola minor is characterized by milder 
clinical signs, smaller skin lesions and a low mortality rate; variola major is 
characterized by more severe disease and scarring and a higher mortality rate.  
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Approximately 5 to 10% of individuals develop flat–
type or hemorrhagic variants of variola major. The 
hemorrhagic form is more common in pregnant women. 
Patients with this form have more severe initial symptoms, 
which are followed by generalized erythema and 
hemorrhages in the skin and mucosa. The initial symptoms 
are similar in the malignant or ‘flat’ form; in this form, 
confluent, flat nonpustular lesions develop and the 
epidermis often peels in survivors. The hemorrhagic and 
malignant forms are usually fatal.  
Communicability 
Yes. Patients are known to be infectious from the time 
the rash appears and remain infectious until the time the 
scabs have separated (approximately 7 to 10 days). Some 
sources recommend quarantine for all contacts for 17 days 
post–exposure. 
Diagnostic Tests 
Smallpox is usually diagnosed by finding the 
characteristic viruses in skin scrapings examined by 
electron microscopy. Aggregations of virus particles called 
Guarnieri bodies are found under the light microscope. 
Gispen’s modified silver stain can demonstrate Guarnieri 
bodies in vesicular scrapings; this test is rapid but relatively 
insensitive.  
Differentiation of variola from vaccinia, monkeypox or 
cowpox requires virus isolation and identification. Variola, 
vaccinia, monkeypox and cowpox viruses look similar in 
most cell culture systems but can be distinguished by their 
characteristic lesions on the chorioallantoic membranes of 
10 to 12 day old chick embryos. Other biological tests are 
occasionally necessary for confirmation. A new polymerase 
chain reaction technique is expected to be an easier and 
more accurate method to identify closely related viruses as 
well as viral strains. In a confirmed outbreak, most cases 
are diagnosed clinically.  
During recovery, patients develop high titers of 
hemagglutinin–inhibiting, neutralizing and complement 
fixing antibodies; antibodies to related viruses can be 
identified by cross–absorption studies. 
Treatment and Vaccination 
No effective treatment other than supportive therapy is 
known; cidofovir and other antiviral agents are under 
investigation.  
An effective human vaccine is available and appears to 
be protective for at least 3 years. Vaccination after exposure 
can prevent disease or reduce clinical signs and the risk of 
death; vaccination is most effective if it is given within a 
few days after exposure. Vaccinia Immune Globulin (VIG) 
may also be helpful in post–exposure prophylaxis. Vaccines 
are contraindicated in immunosuppressed persons, those 
infected with HIV, persons with eczema, and people with 
three or more cardiac risk factors. Rare vaccine 
complications may include generalized vaccinia, 
progressive vaccinia, and postvaccinial encephalitis (which 
has a 25% fatality rate). 
Morbidity and Mortality 
Natural smallpox infections spread slowly, with 
infections transmitted mainly to family members and other 
close personal contacts. Aerosolized virus in biological 
weapons would be expected to infect large numbers of 
individuals; younger people have no immunity against this 
disease and the resistance of those vaccinated more than 10 
years ago is unknown. 
Variola minor is a milder disease; the mortality rate is 
approximately 1% in unvaccinated persons. The overall 
mortality rate for variola major is 3% in vaccinated 
individuals and 30% in unvaccinated; mortality is generally 
higher with the Asian form than African form and in 
children under a year old. The malignant and hemorrhagic 
forms of variola major develop in approximately 5 to 10% 
of infected people. These forms are almost always fatal; the 
mortality rate in the malignant form is 95%. 
In the past, serious vaccine complications occurred in 
approximately 100 per million primary vaccinations. The 
risk of complications is higher in people with eczema, HIV 
or other immunosuppressive diseases, pregnant women, and 
those receiving cancer chemotherapy or radiation. In the 
2003 vaccination campaign of civilians and military 
personnel, it was discovered that people with three or more 
cardiac risk factors should defer the vaccine. Those risk 
factors include being a current smoker or tobacco user, 
having high blood pressure, high cholesterol or 
triglycerides, high blood sugar, and/or a heart condition 
before age 50 in a parent, brother or sister. 
Infections in Animals 
Humans are the only mammals that are naturally 
susceptible to infection. Recently, Peter Jahrling’s group at 
the U.S. Army Medical Research Institute of Infectious 
Diseases (USAMRIID) was able to infect cynomolgus 
monkeys with variola virus. Monkeys were infected with 
extremely high doses by either injection alone or both 
injection and aerosols. All of the research animals became 
ill and 12 of 14 animals died. Virus was found in skin 
pustules. Details of this experiment have not been 
published. 
Internet Resources 
Centers for Disease Control and Prevention (CDC) 
Smallpox Pages 
http://www.bt.cdc.gov/agent/smallpox/index.asp  
Medical Microbiology 
http://www.ncbi.nlm.nih.gov/books/NBK7627 
Medical Treatment and Response to Suspected Smallpox: 
Information for Health Care  
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Providers During Biologic Emergencies (New York 
City Department of Health Bureau of Communicable 
Disease) 
http://www.nyc.gov/html/doh/html/cd/smallmd.html  
“Smallpox and Vaccinia.” In Vaccines, 3rd edition 
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.Vi
ew..ShowSection&rid=vacc.chapter.d1e2084  
The Merck Manual 
http://www.merck.com/pubs/mmanual/  
USAMRIID’s Medical Management of Biological 
Casualties Handbook 
http://www.vnh.org/BIOCASU/toc.html  
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